FORM 3

UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPRO	VAL
OMB	3235-
Number:	0104
Estimated average	ge
burden hours pei	٢
response	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)											
1. Name and Address of Reporting		_		ng 3. Issuer Name and Ticker or Trading Symbol							
Person *	Statem (Mont)	.ent n/Day/Year	Cellectar	Cellectar Biosciences, Inc. [CLRB]							
Longcor Jarrod	07/15	•	,	4.79.1.1	1 .	CD .:	1	70.4	1		
(Last) (First) (Middl C/O CELLECTAR	e)								5. If Amendment, Date Original Filed(Month/Day/Year)		
BIOSCIENCES, INC., 3301						applicable)	1	iica(wio	iiii/Day/1 cai)		
AGRICULTURE DRIVE			Director	Director X Officer (give							
(Street)				title below) below)				5. Individual or Joint/Group			
				Sr. VP o	Sr. VP of Corp Dev & Ops				Filing(Check Applicable Line)		
MADISON, WI 53716								rm filed by One Reporting Person m filed by More than One Reporting			
							P	erson			
(City) (State) (Zip)	Tal	ole I	- Non-Deriva	tive	Securities	Benef	ficially	Owned		
1.Title of Security			of Securities 3.				Nature of Indirect Beneficial				
(Instr. 4)			lly Owned		wnership orm: Direct	Ownership					
		(IIIS	tr. 4)			on or	illsu. 5	,			
					Ìne	direct (I)					
					(Ir	nstr. 5)					
Reminder: Report on a separate line	for each clas	s of securit	ies hei	neficially owned	l dire	ctly or indire	ectly		SEC 1473 (7-02)		
				of information		•		orm ar			
not required				m displays a							
number.											
Table II - Derivative Se	ecurities Ben	eficially O	wned	(e.g., puts, calls	s, wai	rrants, optic	ons, con	vertibl	e securities)		
1. Title of Derivative Security	2. Date Exer		3. Title and Amount of			4.	5.		6. Nature of Indirect		
(Instr. 4)		nd Expiration Date		, .		Conversion		ership	Beneficial Ownership		
	(Month/Day/Yea	ar)	Derivative Security (Instr. 4)			or Exercise Price of		of ative	(Instr. 5)		
	Data	E-mination	`	· 4)		Derivative	Secui				
	Date Exercisable		Title A	A		Security	Direc				
	2.1010104010			Amount or Num of Shares	nber			direct			
				or shares			(I) (Instr	. 5)			
							(IIISti	. 3)			
Dan antin a Orana											
Reporting Owners											
	Relationships										
Reporting Owner Name / A							Other				
Longcor Jarrod		Director	2070	701 (3111001				Julion			
II Ongcor Iarrod											

Sr. VP of Corp Dev & Ops

Signatures

MADISON, WI 53716

3301 AGRICULTURE DRIVE

/s/ Chad Kolean, attorney-in-fact for Jarrod Longcor	08/12/2016
**Signature of Reporting Person	Date

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Exhibit List Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated Paul Bork, Gabrielle Bernstein, Chad Kolean and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Paul Bork, Gabrielle Bernstein, Chad Kolean and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Paul Bork, Gabrielle Bernstein, Chad Kolean and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

Dated: July 15, 2016 Signed: /s/ Jarrod Longcor

Print Name: Jarrod Longcor